Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
search
Join
FREE
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
Join
FREE
Pharma News, Views & Analysis
Filter
News
Articles
Podcasts
Infographics
Advertise With Us
Advertise With Us
US pharma tariffs: What they mean for drug prices
US drug tariffs may not hit branded prices hard, but generics and supply chains face disruption. Here’s what pharma leaders need to know.
Read more
GSK pledges £45m to new antimicrobial resistance initiative
GSK has pledged £45m to the Fleming Initiative, a UK scheme to tackle antimicrobial resistance, led by Imperial College Healthcare NHS Trust and Imperial College London.
Pfizer and AstraZeneca to invest nearly $1bn in France
Pfizer and AstraZeneca have set their sights on France with major investments totalling nearly 1bn (USD) ahead of the country’s annual ‘Choose France’ business summit.
Spotlight: April 2024
Catch up on the top stories to come from the pharma industry over April, including new collaborations set to improve treatments for patients, the latest approvals and more.
Poor return on investment rates on the rise
The pharma industry’s ability to recoup costs on their drug development pipeline was in trouble, been is the downward spiral coming to an end? Read more.
Orphan drugs face new pressures
The orphan drug market has seen robust growth over the past decade, but may face challenges in maintaining its trajectory due to evolving investor and payer preferences.
Spotlight: March 2024
Catch up on March’s top pharma news, including companies slashing inhaler costs and new hope for the UK life sciences sector.
Say hello to EMJ GOLD!
Join us for the next chapter of GOLD as we launch on our new home here on the EMJ website, providing you with a one-stop-shop for all your healthcare content needs.
Spotlight: February 2024
GOLD looks back on some of the top pharma news stories from the past month, including new approvals, the latest appointments and departures in the industry and more.
Loading posts...
« Previous
1
…
17
18
19
20
21
…
26
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View